Rectal Cancer (Stage III)
24
6
10
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 24 trials
100.0%
+13.5% vs benchmark
13%
3 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (24)
Diagnostic Accuracy and Prognostic Value of 18F FDG PET-CT in the Follow up of Patients With Colorectal Carcinoma.
Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer
Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression
Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer
The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial
Can Neoadjuvant Chemoradiotherapy be Ommited in Mid-rectal Cancer
Bovine Reinforcement in Stomach, Colorectal and Lung Operation
Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients
ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer
The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer
TNT to Increase the Clinical Complete Response Rate for Distal LARC
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Sentinel Lymph Node Biopsy in Rectal Cancer
Using Artificial Intelligence to Predict Rectal Cancer Outcomes
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer